378,550 Shares in BioLife Solutions, Inc. $BLFS Purchased by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd purchased a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 378,550 shares of the medical equipment provider’s stock, valued at approximately $9,153,000. BioLife Solutions comprises 2.2% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 12th largest position. Capricorn Fund Managers Ltd owned approximately 0.79% of BioLife Solutions as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BLFS. Qube Research & Technologies Ltd raised its stake in shares of BioLife Solutions by 2,399.5% in the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock worth $5,352,000 after purchasing an additional 238,533 shares during the last quarter. Summit Creek Advisors LLC bought a new stake in BioLife Solutions during the third quarter worth $4,905,000. Ameriprise Financial Inc. raised its position in BioLife Solutions by 11.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock valued at $23,271,000 after buying an additional 109,959 shares during the last quarter. Deerfield Management Company L.P. raised its position in BioLife Solutions by 713.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 111,195 shares of the medical equipment provider’s stock valued at $2,837,000 after buying an additional 97,525 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in BioLife Solutions by 16.9% during the 2nd quarter. Bank of America Corp DE now owns 671,731 shares of the medical equipment provider’s stock valued at $14,469,000 after acquiring an additional 97,354 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Karen A. Foster sold 96,923 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $20.15, for a total value of $1,952,998.45. Following the sale, the insider directly owned 113,742 shares in the company, valued at approximately $2,291,901.30. The trade was a 46.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Troy Wichterman sold 990 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total transaction of $25,334.10. Following the sale, the chief financial officer directly owned 150,746 shares in the company, valued at approximately $3,857,590.14. This trade represents a 0.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 101,956 shares of company stock valued at $2,068,241. 2.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on BLFS shares. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research note on Monday, December 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Northland Securities set a $34.00 target price on shares of BioLife Solutions in a research report on Monday, January 5th. Finally, Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $19.51 on Monday. BioLife Solutions, Inc. has a twelve month low of $17.86 and a twelve month high of $29.62. The firm has a 50 day moving average price of $21.12 and a 200-day moving average price of $24.15. The company has a market capitalization of $942.33 million, a P/E ratio of -177.35 and a beta of 2.00.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.